Feb 7 (Reuters) – Hims & Hers said in a statement on Saturday that it will stop offering access to the compounded semaglutide pill after the U.S. Food and Drug Administration said it would take action against the telehealth provider for its $49 weight-loss pill. (Reporting by Anusha Shah in Bengaluru; Editing by Andrea Ricci)
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
VIDEO SHOWS: ATP 500 CHINA OPEN SEMI-FINAL HIGHLIGHTS - NOVAK DJOKOVIC V DANIIL MEDVEDEV WITH…
Surat (Gujarat) [India], October 5: The installation ceremony of the newly elected office-bearers of the…
ISRAELI FOREIGN MINISTER'S SPOKESPERSON TO REUTERS: CONSULATE WILL STILL CLOSE ON THURSDAY, OCTOBER 8, AS…
LONDON, Oct 5 (Reuters) - Meta, TikTok and X are challenging British regulator Ofcom over…
LONDON, Oct 5 (Reuters) - Meta, TikTok and X are challenging British regulator Ofcom over…
KENYA'S CAPITAL MARKETS REGULATOR: HAS APPROVED A SHORT FORM PROSPECTUS FOR A GLOBAL DEPOSITORY RECEIPT…